Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 16/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 16/20 | 0.47 |
| ▸ | FLT3 | P36888 | 2/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | HTR5A | P47898 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16450076 | 0.74 | HTR7 (0.51) | MKNK1MKNK2FLT3HTR7 | |
| SCHEMBL4906864 | 0.72 | MKNK1 (0.71) | MKNK1MKNK2 | |
| SCHEMBL4905848 | 0.69 | MKNK1 (0.66) | MKNK1MKNK2 | |
| SCHEMBL4907136 | 0.65 | MKNK1 (0.55) | MKNK1MKNK2 | |
| SCHEMBL18803536 | 0.65 | MKNK1 (1.00) | MKNK1MKNK2 | |
| SCHEMBL3645075 | 0.65 | MKNK1 (0.60) | MKNK1MKNK2 | |
| SCHEMBL28133994 | 0.64 | HPGD (0.59) | MKNK1MKNK2 | |
| SCHEMBL12644984 | 0.63 | KCNH3 (0.58) | MKNK1MKNK2 | |
| SCHEMBL15584142 | 0.63 | FLT3 (0.56) | MKNK1MKNK2FLT3 | |
| SCHEMBL18803533 | 0.62 | MKNK1 (1.00) | MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7956060-B2 | Pyrimidine derivative compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-06-07 | — | — | US | disclosed |
| US-20090012060-A1 | Antitumor Agent | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1749827-A1 | ANTI-TUMOR AGENT | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012060-A1 | Antitumor Agent | NR1H3, NR1I3, NR0B1 | MKNK1 2072/4885MKNK2 2559/4885FLT3 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.